Jorey Chernett's Schedule 13G Filing for Lineage Cell Therapeutics, Inc.

Jorey Chernett has filed a Schedule 13G with the SEC, disclosing beneficial ownership of 11,445,003 shares of common stock in Lineage Cell Therapeutics, Inc., representing 5.01% of the company's outstanding shares. The filing indicates that Chernett has sole voting and dispositive power over these shares. The filing is made under Rule 13d-1(c) and certifies that the shares were not acquired for the purpose of influencing the control of the issuer. The filing was signed on September 25, 2025.